Jiménez-Yuste, V. (Víctor)

Filtering

2020 - 20233

Settings

Author search.filters.isAuthorOfPublication.4d1124c4-959b-420e-9564-132881ebf16c

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
    (2023) García-Gutiérrez, V. (Valentín); Trilla, A. (Antoni); Palomo, E. (Esteban); Ruiz-Galiana, J. (Julián); García-Sanz, R. (Ramón); Martin-Delgado, M.C. (Mari Cruz); Martínez, J. (Joaquin); Rodríguez-Lescure, Á. (Álvaro); Bouza, E. (Emilio); Tejerina-Picado, F. (Francisco); Pozo, J.L. (José Luis) del; Barragán, B. (Begoña); Guillem, V. (Vicente); Aragonés, N. (Nuria); Martín, M. (Miguel); Gracia, D. (Diego); Sureda-Balari, A. M. (Anna Maria); Zapatero, A. (Antonio); Lopez, R. (Rafael); Cámara, R. (Rafael) de la; San-Miguel, J.F. (Jesús F.); Alés, J.E. (José Enrique); Jiménez-Yuste, V. (Víctor)
    We do not know the precise figure for solid organ tumors diagnosed each year in Spain and it is therefore difficult to calculate whether there has been a decrease in cancer diagnoses as a consequence of the pandemic. Some indirect data suggest that the pandemic has worsened the stage at which some non-hematological neoplasms are diagnosed. Despite the lack of robust evidence, oncology patients seem more likely to have a poor outcome when they contract COVID-19. The antibody response to infection in cancer patients will be fundamentally conditioned by the type of neoplasia present, the treatment received and the time of its administration. In patients with hematological malignancies, the incidence of infection is probably similar or lower than in the general population, due to the better protective measures adopted by the patients and their environment. The severity and mortality of COVID-19 in patients with hematologic malignancies is clearly higher than the general population. Since the immune response to vaccination in hematologic patients is generally worse than in comparable populations, alternative methods of prevention must be established in these patients, as well as actions for earlier diagnosis and treatment. Campaigns for the early diagnosis of malignant neoplasms must be urgently resumed, post-COVID manifestations should be monitored, collaboration with patient associations is indisputable and it is urgent to draw the right conclusions to improve our preparedness to fight against possible future catastrophes.
  • Thumbnail Image
    Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere covid-19 pneumonia (bemicop study): an open-label, multicenter, randomized, controlled trial
    (2022) Marcos-Jubilar, M. (María); Carmona-Torre, F. (Francisco de A.); Vidal, R. (Rosa); Ruiz-Artacho, P. (Pedro); Filella, D. (David); Carbonell, C. (Cristina); Jiménez-Yuste, V. (Víctor); Schwartz, J. (Juana); Llamas, P. (Pilar); Alegre, F. (Félix); Sadaba, B. (Belén); Nuñez-Cordoba, J.M. (Jorge M.); Yuste, J.R. (José Ramón); Fernández-García, J. (Javier); Lecumberri, R. (Ramón)
    Thromboprophylaxis with low molecular weight heparin in hospitalized patients with COVID-19 is mandatory, unless contraindicated. Given the links between inflammation and thrombosis, the use of higher doses of anticoagulants could improve outcomes. We conducted an open-label, multicenter, randomized, controlled trial in adult patients hospitalized with nonsevere COVID-19 pneumonia and elevated D-dimer. Patients were randomized to therapeutic-dose bemiparin (115 IU/kg daily) versus standard prophylaxis (bemiparin 3,500 IU daily), for 10 days. The primary efficacy outcome was a composite of death, intensive care unit admission, need of mechanical ventilation support, development of moderate/severe acute respiratory distress, and venous or
  • Thumbnail Image
    Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak
    (2020) López, A. (Andrés); de la Cruz-Benito, B. (Beatriz); Lopez-de-la-Guía, A. (Ana); de Soto-Álvarez, T. (Teresa); Sánchez-Vadillo, I. (Irene); Dos-Santos-Ortas, A. (Abel); Casado-Abad, G. (Gema); Canales-Albendea, M. A. (Miguel Ángel); Lázaro-Del-Campo, P. (Paula); Humala-Barbier, K. (Karem); Jiménez-Yuste, V. (Víctor)
    The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.